ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/20/2023
Back to search
Official data from USPTO
PLX PHARMA INC.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
09/20/2023
Trademark type
Combined
Nice classes
5
Filing date
09/17/2020
Registration date
12/14/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/14/2021
Last transaction
12/14/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
08/14/2021
First use in commerce
08/14/2021
Drawing code
3
Owner type
16
Owner location
BUFFALO, NY, US
Examiner
LEASER, ANDREW
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letters "PLX", in blue with part of the "X" in red, above the words "PHARMA INC.'', in blue.
Holders and representatives
Holders
PLX ACQUISITION COMPANY, LLC
PLX PHARMA INC.
Representatives
Mary L. Grieco OLSHAN FROME WOLOSKY LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Aspirin; Pain relief medication; Fever relief medication; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of arthritisrheumatoid arthritisosteoarthritis; Cardiovascular pharmaceuticals; Pharmaceutical treatments for the prevention and treatment of vascular disease; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for treating hypertension; Pharmaceutical products for treating diabetes; Pharmaceuticals in the field of human medicine
Publications
History of USPTO decisions and trademark events.
21 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/14/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/06/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/05/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/22/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/22/2021
IUAF
USE AMENDMENT FILED
10/07/2021
EISU
TEAS STATEMENT OF USE RECEIVED
10/07/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/13/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/16/2021
PUBO
PUBLISHED FOR OPPOSITION
02/16/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/27/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/11/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
01/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
01/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/11/2021
DOCK
ASSIGNED TO EXAMINER
01/08/2021
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/27/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/26/2020
NWAP
NEW APPLICATION ENTERED
09/21/2020
Continuous trademark protection
Get notified about every new filing that threatens PLX PHARMA INC. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.